Could a daily pill shrink painful NF1 tumors? new global trial seeks answers.
NCT ID NCT04924608
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 38 times
Summary
This study tests the drug selumetinib in adults with neurofibromatosis type 1 (NF1) who have painful, inoperable nerve tumors called plexiform neurofibromas. About 145 participants worldwide will receive either selumetinib or a placebo to see if the drug can shrink tumors and reduce pain. The goal is to control the disease and improve quality of life, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Gainesville, Florida, 32610, United States
-
Research Site
Rockville, Maryland, 20852, United States
-
Research Site
St Louis, Missouri, 63156, United States
-
Research Site
Commack, New York, 11725, United States
-
Research Site
Melbourne, 3000, Australia
-
Research Site
St Leonards, 2065, Australia
-
Research Site
Porto Alegre, 90035-903, Brazil
-
Research Site
Ribeirão Preto, 14051-140, Brazil
-
Research Site
São Paulo, 045202-001, Brazil
-
Research Site
Toronto, Ontario, M5G 2C4, Canada
-
Research Site
Montreal, Quebec, H4A 3J1, Canada
-
Research Site
Beijing, 100070, China
-
Research Site
Beijing, 100730, China
-
Research Site
Guangzhou, 510060, China
-
Research Site
Shenyang, 110001, China
-
Research Site
Créteil, 94000, France
-
Research Site
Lyon, 69008, France
-
Research Site
Toulouse, 31059, France
-
Research Site
Hamburg, 20246, Germany
-
Research Site
Tübingen, 72076, Germany
-
Research Site
Würzburg, 97080, Germany
-
Research Site
Milan, 20133, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Roma, 00165, Italy
-
Research Site
Minatoku, 105-8471, Japan
-
Research Site
Nagoya, 466-8560, Japan
-
Research Site
Shinjuku-ku, 160-8582, Japan
-
Research Site
Bydgoszcz, 85-094, Poland
-
Research Site
Moscow, 115522, Russia
-
Research Site
Moscow, 125412, Russia
-
Research Site
Badalona, 08916, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
London, SE1 9RT, United Kingdom
-
Research Site
Manchester, M20 4BX, United Kingdom
Conditions
Explore the condition pages connected to this study.